How DNA damage in tumors affects immune responses
Official title: Tumor cell instrinsic DNA damage signaling to the immune response
Funded at University of Pennsylvania · NIH-11085248 · Data updated 2026-11-12
This study is looking at how cancer cells that have damaged DNA send signals to the immune system, and how those signals can either help or hinder the immune system's ability to fight the cancer, with the goal of finding better ways to treat cancer.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | May 8, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $372,839 |
| NIH project number | 5P01CA265794-03 |
| Project ID | NIH-11085248 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with cancers characterized by DNA damage and those who may benefit from enhanced anti-tumor immune responses.
✕Less likely to help
Patients with cancers that do not exhibit significant DNA damage or those who are not eligible for immunotherapy may not benefit from this research.
What this research studies
This research investigates the relationship between DNA damage in cancer cells and the immune system's response to that damage. It focuses on understanding how cancer cells communicate signals of DNA damage and how these signals can either activate or suppress the immune response against tumors. The study employs various methodologies, including cellular and biochemical techniques, as well as in vivo models, to explore these mechanisms in detail. By examining the role of specific pathways and proteins involved in this signaling, the research aims to uncover new insights that could enhance cancer therapies.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments by enhancing the immune system's ability to fight tumors.
How similar studies have gone: Other research has shown promising results in understanding the immune response to DNA damage, indicating that this approach has potential for significant advancements in cancer treatment.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Greenberg, Roger a — University of Pennsylvania
- Study coordinator: Greenberg, Roger a
Related research
Other NIH-funded projects on the same topics.
-
Comparing universal and guideline-directed genetic testing for young adults with cancer
This study is looking at whether a broader genetic test can help young adults with cancer find inherited risks that regular tests might miss, so they can get better treatment and care tailored just for them.
-
Better, searchable data for human pain biology
A data integration center will standardize, combine, and share molecular and cellular data from human pain research to help scientists understand how pain works and to accelerate discoveries.
-
Understanding how sweat glands form and work to help burn and skin injury patients
A study at the University of Pennsylvania looks at how sweat glands develop and function, with the goal of informing treatments for people who suffer traumatic skin injuries.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Understanding how a special airway cell helps protect and repair breathing passages
A researcher is studying a newly found airway cell called the hillock to see how it protects the airways and helps repair them after injury, with the aim of helping people with asthma, COPD, or bronchiectasis.
-
Defining TMJ cartilage progenitors and their regulatory niche for TMJ regeneration
Researchers are studying the cells that could help repair the jaw’s cartilage in TMJ osteoarthritis to lay the groundwork for regenerative therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.